Zogenix to Participate in the Stifel 3rd Annual CNS Day
Zogenix (NASDAQ: ZGNX) announced that Stephen J. Farr, Ph.D., President and CEO, and Michael Smith, Executive Vice President and CFO, will participate in a fireside chat at the Stifel 3rd Annual CNS Day on March 31, 2021, at 2:30 PM ET. The event will be available for live streaming and will be archived for 90 days on Zogenix's Investor Relations website. The company focuses on developing therapies for rare diseases, including FINTEPLA, approved for Dravet syndrome, and two other late-stage programs targeting Lennox-Gastaut syndrome and TK2 deficiency.
- None.
- None.
EMERYVILLE, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will participate in a fireside chat on Wednesday, March 31, 2021, at the Stifel 3rd Annual CNS Day.
| Zogenix Presentation Details |
| Date: Wednesday, March 31, 2021 |
| Time: 2:30 PM Eastern Time |
The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com.
About Zogenix
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
CONTACTS:
Zogenix
Melinda Baker
Senior Director, Corporate Communications
+1 (510) 788-8732 | corpcomms@zogenix.com
Investors
Brian Ritchie
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | britchie@lifesciadvisors.com
Media
Stefanie Tuck, Vice President, Porter Novelli
+1 (978) 390-1394 | stefanie.tuck@porternovelli.com
FAQ
When is Zogenix participating in the Stifel 3rd Annual CNS Day?
What time is Zogenix's presentation at CNS Day?
Where can I watch Zogenix's presentation?
What therapies is Zogenix developing?
Who are the executives speaking for Zogenix at CNS Day?
